This trial is active, not recruiting.

Condition hepatitis c virus
Treatment insulin
Sponsor McGill University Health Center
Start date January 2011
End date December 2013
Trial size 5 participants
Trial identifier NCT01271140, 10-086-BMA


Insulin resistance is one of the key factors in defining a progressive course of chronic Hepatitis C virus (HCV) infection and hepatic fibrosis. Multiple trials have targeted insulin resistance as an adjuvant way to manage hepatitis C liver disease with promising results.

Long term therapy using high dose insulin was shown to significantly reduce insulin resistance in obese patients. In cardiac and critically ill patients, long term insulin was shown to produce better outcomes mainly by reducing the overt inflammatory response. Furthermore, initial results of ongoing trials are revealing more benefits of insulin therapy. Using the (hyperinsulinimic normoglycemic clamp) for eight hours on patients undergoing major liver resection was able to maximize their liver function post-operatively. This trial also demonstrated inhibition of the inflammatory response, improvement in liver glycogen, inhibition of apoptosis and stimulation of liver regeneration.

Putting in mind the potential ability of the liver to regenerate and regain better function. The anti-inflammatory properties of insulin therapy along with its ability to reduce insulin resistance over time has led us to see the potential benefits of using insulin therapy on patients with chronic hepatitis C virus liver cirrhosis. Insulin will target the pathophysiology of the disease at a cellular and a molecular level.

The investigators theorize that long-term high insulin therapy would be able to promote better liver function and slow down fibrosis and injury in this population of patients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
insulin Hyperinsulinemic normoglycemic clamp
Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.

Primary Outcomes

Liver status improvments (biochemical and histological)
time frame: 6 months

Secondary Outcomes

Insulin resistance
time frame: 6 months
Inflammatory mediators
time frame: 6 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Hepatitis C positive adult patients (serum HCV antibody positive) - MELD score 6-15 at the time of inclusion - Viral genotype "non-3" - Not on antiviral therapy Exclusion Criteria: - HBV or HIV co-infection - Evidence of hepatocellular carcinoma at the start of the trial either by imaging and or AFP levels above 400 - Undetectable HCV viral load (using HCV PCR test) - Recent infection or bleeding (in the last 3 months)

Additional Information

Official title High Dose Insulin Therapy to Improve Liver Function in Patients With HCV Liver Cirrhosis
Principal investigator Peter Metrakos, MD
Trial information was received from ClinicalTrials.gov and was last updated in November 2013.
Information provided to ClinicalTrials.gov by McGill University Health Center.